Buscar
Gilead Sciences Inc
GILDAñadir a la lista de seguimiento
125.160USD
+0.110+0.09%
Cierre 06/24, 16:00（ET）Cotizaciones retrasadas 15 min
155.39BCap. mercado
16.88P/E TTM
Más Datos de Gilead Sciences Inc Compañía
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in more than 35 countries worldwide.
Información de Gilead Sciences Inc
Símbolo de cotizaciónGILD
Nombre de la empresaGilead Sciences Inc
Fecha de salida a bolsaJan 22, 1992
Director ejecutivoO'Day (Daniel P)
Número de empleados17600
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 22
Dirección333 Lakeside Dr
CiudadFOSTER CITY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94404-1147
Teléfono16505743000
Sitio Webhttps://www.gilead.com/
Símbolo de cotizaciónGILD
Fecha de salida a bolsaJan 22, 1992
Director ejecutivoO'Day (Daniel P)
Ejecutivos de Gilead Sciences Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
124.23K
-1.24%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
27.20K
+4.21%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
12.89K
+8.89%
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Mr. Harish Manwani
Mr. Harish Manwani
Independent Director
Independent Director
--
--
Mr. Andrew D. (Andy) Dickinson
Mr. Andrew D. (Andy) Dickinson
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Daniel P. O'Day
Mr. Daniel P. O'Day
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Sandra J. Horning, M.D.
Dr. Sandra J. Horning, M.D.
Independent Director
Independent Director
--
--
Mr. Javier J. Rodriguez
Mr. Javier J. Rodriguez
Independent Director
Independent Director
--
--
Dr. Jeffrey A. (Jeff) Bluestone, Ph.D.
Dr. Jeffrey A. (Jeff) Bluestone, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
124.23K
-1.24%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
27.20K
+4.21%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
12.89K
+8.89%
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Mr. Harish Manwani
Mr. Harish Manwani
Independent Director
Independent Director
--
--
Mr. Andrew D. (Andy) Dickinson
Mr. Andrew D. (Andy) Dickinson
Chief Financial Officer
Chief Financial Officer
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Gilead Sciences Inc?
Los cinco principales accionistas de Gilead Sciences Inc son: Ms. Johanna Mercier
¿Cuántas instituciones poseen acciones de Gilead Sciences Inc (GILD)?
A fecha de 2026Q1, 3702 instituciones poseen acciones de Gilead Sciences Inc, con un valor de mercado combinado de aproximadamente 1.14B, lo que representa el 92.19% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -2548741.00.
¿Cuál es la mayor fuente de ganancias de Gilead Sciences Inc?
El 2026Q1, el segmento empresarial Biktarvy generó la ganancia más alta para Gilead Sciences Inc, ascendiendo a 14.33B y representando el 48.68% de la ganancia total.
